JVATiTD - Articles

Official publication of CEVAP/UNESP
Review

Therapeutic potential of iron oxide nanoparticles for cutaneous leishmaniasis: a systematic review of in vitro and in vivo studies

Priscila de Cássia da Silva1, Bruna de Macedo Lima1, Camila Sales Nascimento1, Anna Carolina Pinheiro Lage2, Celso Pinto de Melo3, Carlos Eduardo Calzavara-Silva1, Érica Alessandra Rocha Alves1 [ + show more ]

J Venom Anim Toxins incl Trop Dis, 2025, 31:e20250004
Received: 12 February 2025 | Accepted: 27 June 2025 | Published online: 03 October 2025
https://doi.org/10.1590/1678-9199-JVATITD-2025-0004

Abstract

The treatment of cutaneous leishmaniasis (CL) is challenged by limited therapeutic options, high drug toxicity, and frequent treatment failure. In this context, iron oxide nanoparticles (IONPs) have emerged as promising therapeutic alternatives. This review summarizes experimental findings on the in vitro and in vivo anti-Leishmania activity of IONPs, highlighting their potential as a treatment for CL. A systematic search of PubMed, ScienceDirect, and Scopus identified 16 studies evaluating the anti-Leishmania effects of IONPs across various CL models. The studies assessed IONPs' physicochemical properties (size, shape, polydispersity index, and zeta potential), functionalization strategies, and efficacy against axenic and intracellular Leishmania forms, as well as in animal models. Most studies investigated spherical IONPs ranging from 5 to 90 nm, with polydispersity index values between 0.2 and 1.0 and zeta potentials from -13 mV to +35 mV. Functionalization improved dispersion and enabled antimicrobial conjugation. IONPs reduced axenic Leishmania viability, decreased intracellular parasitism, and lowered parasite loads in infected mouse lesions. In vitro, parasite death was linked to lysosomal rupture, oxidative stress, apoptosis, necrosis, and nitric oxide production by macrophages. In vivo, treated animals exhibited reduced parasite burdens, milder lesions, and enhanced IFN-γ production, suggesting improved immune responses. Despite these promising effects, issues such as formulation optimization, biocompatibility, and evaluation of pharmacokinetics and pharmacodynamics remain to be addressed. IONPs represent a novel and promising dual-action therapeutic strategy for CL, combining antiparasitic effects with immune modulation. However, important knowledge gaps persist regarding their mechanisms of action, long-term safety, efficacy across different Leishmania species and clinical scenarios. Further research is needed to advance IONPs as a safe and effective treatment for CL.

 

Keywords: Nanoparticles; Iron oxide; Cutaneous leishmaniasis; Leishmania; Antiprotozoal agents; Nanomedicine; Systematic review.

Full Article PDF
Top